Your browser doesn't support javascript.
loading
The efficacy of onabotulinumtoxinA in patients with previous failed augmentation cystoplasty: Cohort series and literature review.
Toia, Bogdan; Pakzad, Mahreen H; Hamid, Rizwan; Wood, Dan N; Greenwell, Tamsin J; Ockrim, Jeremy L.
Affiliation
  • Toia B; Department of Urology, University College London Hospital, London, UK.
  • Pakzad MH; Department of Urology, University College London Hospital, London, UK.
  • Hamid R; Department of Urology, University College London Hospital, London, UK.
  • Wood DN; Department of Urology, University College London Hospital, London, UK.
  • Greenwell TJ; Department of Urology, University College London Hospital, London, UK.
  • Ockrim JL; Department of Urology, University College London Hospital, London, UK.
Neurourol Urodyn ; 39(6): 1831-1836, 2020 08.
Article in En | MEDLINE | ID: mdl-32572987
ABSTRACT

AIMS:

To investigate the role of onabotulinumtoxinA (BTX-A) injections in patients with failed augmentation cystoplasty for neuropathic or idiopathic detrusor overactivity (NDO or IDO).

METHODS:

A retrospective review of all cystoplasty patients who underwent onabotulinumtoxinA injection at a tertiary center between 2008 and 2019 was performed. Details including indications and time from cystoplasty, video-urodynamic parameters, onabotulinumtoxinA dose, and clinical outcomes were analyzed. Telephone interview was performed for patients that requested repeat onabotulinumtoxinA injections. The interview included a modified PGIC7 and UDI6 questionnaires. A positive clinical response was considered improvement of overactive symptoms sufficient to merit repeat onabotulinumtoxinA injection and a modified PGIC7 of four or above.

RESULTS:

Thirty patients were identified (11 men and 19 women). The indications for augmentation were IDO (n = 18) or NDO (n = 12). Mean age at the time of cystoplasty was 42 years (range, 10-61). Interval between cystoplasty and initial onabotulinumtoxinA was 98 months (range, 3-271). Video-urodynamics before onabotulinumtoxinA revealed low compliance in 13 patients, DO in 22 patients, and combined low compliance/DO in 10. The median maximum cystometric bladder capacity was 338 mL (range, 77-570 mL). Thirteen patients responded to onabotulinumtoxinA injections. Higher peak DO pressure was associated with a significantly higher chance that the patient would experience benefit from the injections P = .026). The patients that responded to onabotulinumtoxin A underwent a total of 115 procedures (mean, 8.8 injections) over a mean 88 months (range, 20-157 months).

CONCLUSIONS:

Forty-three percent of patients responded well to intra-detrusor onabotulinumtoxinA injections. This avoided the need for more invasive surgery and had a positive impact on their quality of life.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quality of Life / Botulinum Toxins, Type A / Urinary Bladder, Overactive Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Aspects: Patient_preference Limits: Adolescent / Adult / Child / Female / Humans / Male / Middle aged Language: En Journal: Neurourol Urodyn Year: 2020 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quality of Life / Botulinum Toxins, Type A / Urinary Bladder, Overactive Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Aspects: Patient_preference Limits: Adolescent / Adult / Child / Female / Humans / Male / Middle aged Language: En Journal: Neurourol Urodyn Year: 2020 Document type: Article Affiliation country: